BG-C477

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameBG-C477
Drug Alias NameBG-C-477
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CEADNA topoisomerase inhibitors
TargetsCarcinoembryonic antigenDNA topoisomerase
Therapy Area/IndicationsSolid tumoursLung NeoplasmsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesThailandNew Zealand +[6
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A